We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will J&J (JNJ) Initiate Pharma Q2 Earnings With a Beat?
Read MoreHide Full Article
We expect Johnson & Johnson’s (JNJ - Free Report) second-quarter 2021 results, slated on Jul 21, before market open, to beat expectations. In the last reported quarter, the company delivered an earnings surprise of 12.12%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 9.19%, on average.
J&J’s stock has risen 6.8% this year so far against a decrease of 9.8% for the industry.
Image Source: Zacks Investment Research
Factors to Consider
J&J’s Pharma segment is expected to have continued to outperform the market led by increased penetration and new indications across key products such as Darzalex, Imbruvica, Stelara and Erleada.
The Zacks Consensus Estimate for Imbruvica, Darzalex and Stelara is pegged at $1.15 billion, $1.28 billion and $2.16 billion, respectively.
Other core products like Invega Sustenna, J&J’s pulmonary arterial hypertension (PAH) drugs and new drugs, Erleada and Tremfya might have contributed significantly to sales growth.
Improvement in sales of some other key drugs like Xarelto seen in the past few quarters is likely to have continued into the second quarter. J&J’s single-dose COVID-19 vaccine, which was approved for emergency use in some countries this year, generated sales of $100 million in the first quarter. Sales of the vaccine are likely to have been higher in the second quarter.
Generic/biosimilar competition to drugs like Zytiga and Remicade and some negative impact of COVID-19 are likely to have hurt the top line.
The Zacks Consensus Estimate for sales in the Pharma segment are $6.54 billion.
With regard to the Medical Devices segment, sales are likely to have benefited from continued market recovery amid ramping up of medical procedures, better execution and new product launches. In fact, the highest quarterly growth of the year is expected to have occurred in the second quarter due to easy comparison to the highly disrupted second quarter of 2020. It also remains to be seen how market variables such as patient willingness to take insurance coverage, and unemployment rates along with the easing of mobility restrictions has influenced the rate of recovery. The Zacks Consensus Estimate for sales in the Medical Devices segment is pegged at $6.54 billion.
In the Consumer Healthcare segment, the negative COVID-related sales comparisons, which hurt sales in the first quarter are likely to have reversed in the second quarter. Sales growth is expected to have been normalized in the second quarter. Listerine mouthwash in oral care products and international skin health/beauty products are likely to have done well in the second quarter. The Zacks Consensus Estimate for sales in the Consumer segment is pegged at $3.58 billion.
Importantly, investors will also focus on whether J&J updates its financial outlook for 2021.
Key Approvals in Q2
In May, the FDA granted accelerated approval to J&J’s Rybrevant (amivantamab) for the treatment of non-small cell lung cancer (NSCLC) that targets EGFR exon 20 insertion mutations, as detected by an FDA-approved test. In the same month, the European Commission granted approval to Ponvory (ponesimod), an oral treatment for relapsing forms of multiple sclerosis (RMS). Ponvory was approved by the FDA in March. The company is expected to discuss its commercialization plans for these drugs on the second-quarter conference call.
Earnings Whispers
Our proven model predicts an earnings beat for J&J in the to-be-reported quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. This is the case here, as elaborated below.
Earnings ESP: J&J’s Earnings ESP is +0.44% as the Most Accurate Estimate of $2.29 is higher than the Zacks Consensus Estimate of $2.28. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: J&J has a Zacks Rank #3
Other Stocks to Consider
Here are some other large drug stocks that have the right combination of elements to beat on earnings this time around:
Image: Bigstock
Will J&J (JNJ) Initiate Pharma Q2 Earnings With a Beat?
We expect Johnson & Johnson’s (JNJ - Free Report) second-quarter 2021 results, slated on Jul 21, before market open, to beat expectations. In the last reported quarter, the company delivered an earnings surprise of 12.12%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 9.19%, on average.
J&J’s stock has risen 6.8% this year so far against a decrease of 9.8% for the industry.
Image Source: Zacks Investment Research
Factors to Consider
J&J’s Pharma segment is expected to have continued to outperform the market led by increased penetration and new indications across key products such as Darzalex, Imbruvica, Stelara and Erleada.
The Zacks Consensus Estimate for Imbruvica, Darzalex and Stelara is pegged at $1.15 billion, $1.28 billion and $2.16 billion, respectively.
Other core products like Invega Sustenna, J&J’s pulmonary arterial hypertension (PAH) drugs and new drugs, Erleada and Tremfya might have contributed significantly to sales growth.
Improvement in sales of some other key drugs like Xarelto seen in the past few quarters is likely to have continued into the second quarter. J&J’s single-dose COVID-19 vaccine, which was approved for emergency use in some countries this year, generated sales of $100 million in the first quarter. Sales of the vaccine are likely to have been higher in the second quarter.
Generic/biosimilar competition to drugs like Zytiga and Remicade and some negative impact of COVID-19 are likely to have hurt the top line.
The Zacks Consensus Estimate for sales in the Pharma segment are $6.54 billion.
With regard to the Medical Devices segment, sales are likely to have benefited from continued market recovery amid ramping up of medical procedures, better execution and new product launches. In fact, the highest quarterly growth of the year is expected to have occurred in the second quarter due to easy comparison to the highly disrupted second quarter of 2020. It also remains to be seen how market variables such as patient willingness to take insurance coverage, and unemployment rates along with the easing of mobility restrictions has influenced the rate of recovery. The Zacks Consensus Estimate for sales in the Medical Devices segment is pegged at $6.54 billion.
In the Consumer Healthcare segment, the negative COVID-related sales comparisons, which hurt sales in the first quarter are likely to have reversed in the second quarter. Sales growth is expected to have been normalized in the second quarter. Listerine mouthwash in oral care products and international skin health/beauty products are likely to have done well in the second quarter. The Zacks Consensus Estimate for sales in the Consumer segment is pegged at $3.58 billion.
Importantly, investors will also focus on whether J&J updates its financial outlook for 2021.
Key Approvals in Q2
In May, the FDA granted accelerated approval to J&J’s Rybrevant (amivantamab) for the treatment of non-small cell lung cancer (NSCLC) that targets EGFR exon 20 insertion mutations, as detected by an FDA-approved test. In the same month, the European Commission granted approval to Ponvory (ponesimod), an oral treatment for relapsing forms of multiple sclerosis (RMS). Ponvory was approved by the FDA in March. The company is expected to discuss its commercialization plans for these drugs on the second-quarter conference call.
Earnings Whispers
Our proven model predicts an earnings beat for J&J in the to-be-reported quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. This is the case here, as elaborated below.
Earnings ESP: J&J’s Earnings ESP is +0.44% as the Most Accurate Estimate of $2.29 is higher than the Zacks Consensus Estimate of $2.28. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: J&J has a Zacks Rank #3
Other Stocks to Consider
Here are some other large drug stocks that have the right combination of elements to beat on earnings this time around:
GlaxoSmithKline (GSK - Free Report) with an Earnings ESP of +2.47% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Novartis (NVS - Free Report) has an Earnings ESP of +1.97% and a Zacks Rank #3.
Pfizer (PFE - Free Report) has an Earnings ESP of +2.51% and a Zacks Rank #3.